Physicochemical Properties
| Molecular Formula | C17H17NO4 |
| Molecular Weight | 299.32 |
| Exact Mass | 299.116 |
| CAS # | 103188-48-3 |
| PubChem CID | 9994897 |
| Appearance | White to off-white solid powder |
| LogP | 2.566 |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 5 |
| Heavy Atom Count | 22 |
| Complexity | 377 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | C1=CC(=CC=C1CCNC(=O)/C=C/C2=CC(=C(C=C2)O)O)O |
| InChi Key | VSHUQLRHTJOKTA-XBXARRHUSA-N |
| InChi Code | InChI=1S/C17H17NO4/c19-14-5-1-12(2-6-14)9-10-18-17(22)8-4-13-3-7-15(20)16(21)11-13/h1-8,11,19-21H,9-10H2,(H,18,22)/b8-4+ |
| Chemical Name | (E)-3-(3,4-dihydroxyphenyl)-N-[2-(4-hydroxyphenyl)ethyl]prop-2-enamide |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | N-trans-Caffeoyltyramine (2.5-200 μM, 48 h) can down-regulate miR-199a-5p and alter the microRNA expression profile of brain cells, with an IC50 value of 59 μM on human SH-SY5Y (SH) cells. 50% [1]. |
| References |
[1]. Effect of Cannabidiolic Acid, N-Trans-Caffeoyltyramine and Cannabisin B from Hemp Seeds on microRNA Expression in Human Neural Cells. Curr Issues Mol Biol. 2022 Oct 21;44(10):5106-5116. |
| Additional Infomation |
N-cis-Caffeoyltyramine is a member of catechols. n-Caffeoyltyramine has been reported in Ceratostigma willmottianum, Solanum tuberosum, and other organisms with data available. See also: Tobacco Leaf (part of); Cannabis sativa subsp. indica top (part of); Ipomoea aquatica leaf (part of). |
Solubility Data
| Solubility (In Vitro) | DMSO: 250 mg/mL (835.23 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (6.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3409 mL | 16.7045 mL | 33.4091 mL | |
| 5 mM | 0.6682 mL | 3.3409 mL | 6.6818 mL | |
| 10 mM | 0.3341 mL | 1.6705 mL | 3.3409 mL |